Please note that this program was recorded prior to the FDA approval of pralsetinib for RET-mutant medullary thyroid and RET fusion-positive thyroid cancer on December 2, 2020.
Pralsetinib is now indicated for the treatment of:
- Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy
- Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)
The approvals are based on results from the phase I/II ARROW study, which demonstrated durable clinical activity in people with or without prior therapy and regardless of RET alteration genotypes.
Lori Wirth, MD (Program Chair)
Massachusetts General Hospital’s Center for Head and Neck Cancers
Harvard Medical School
This enduring activity will cover the diagnosis, treatment, and management of advanced thyroid cancer.
This educational activity is intended for oncologists and endocrinologists, as well as pathologists, along with their multidisciplinary teams in academic centers and the community setting who are especially challenged in keeping up with the most current data on new and emerging, less commonly occurring genomic alterations, genomic testing methodologies, and optimal treatment decisions for patients with thyroid cancer.
After completing the CME activity, learners should be better able to:
- Utilize best practices for identifying actionable thyroid cancer molecular/genomic alterations in routine clinical practice.
- Integrate available and emerging targeted treatment options into routine clinical practice for the treatment of patients with advanced thyroid cancer based on results showing actionable molecular/genomic alterations.
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in caring for patients with advanced thyroid cancer.
CNE Credits: 1.0 ANCC Contact Hour
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
|Lori Wirth, MD||Consultant||Loxo Oncology, Eli Lilly, Merck, Bayer, BluePoint Laboratories, Cue Biopharma, and Eisai|
CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
Dave Chatman, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Submit the pre- and post-test and evaluation form to Med Learning Group.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com.
RELEASE DATE: February 10, 2021
EXPIRATION DATE: February 10, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group at firstname.lastname@example.org.
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.